Smartphones can be used for patient follow-up after a surgical mission treating complex head and neck disfigurement in Ethiopia: Results from a prospective pilot study

2020 ◽  
Author(s):  
D Bradley ◽  
C Honeyman ◽  
V Patel ◽  
J Zeolla ◽  
L Lester ◽  
...  
Keyword(s):  
Pilot Study ◽  
Head And Neck ◽  
Prospective Pilot Study ◽  
Surgical Mission

scholarly journals Cytokines levels, Severity of acute mucositis and the need of PEG tube installation during chemo-radiation for head and neck cancer - a prospective pilot study

2010 ◽  
Vol 5 (1) ◽  
pp. 16 ◽  
Author(s):  
Amichay Meirovitz ◽  
Michal Kuten ◽  
Salem Billan ◽  
Roxolyana Abdah-Bortnyak ◽  
Anat Sharon ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Pilot Study ◽  
Head And Neck ◽  
Neck Cancer ◽  
Prospective Pilot Study ◽  
Peg Tube

Developing a reliable and cost-effective follow-up programme after a short-term head and neck reconstructive mission in Ethiopia: a pilot study

2020 ◽  
Vol 58 (10) ◽  
pp. e175
Author(s):  
Daniel Bradley ◽  
Calum Honeyman ◽  
Vinod Patel ◽  
Julian Zeolla ◽  
Lucy Lester ◽  
...  
Keyword(s):  
Pilot Study ◽  
Head And Neck ◽  
Cost Effective ◽  
Short Term

scholarly journals A Novel Digital Patient-Reported Outcome Platform for Head and Neck Oncology Patients–-A Pilot Study

2016 ◽  
Vol 9 ◽  
pp. CMENT.S40219 ◽  
Author(s):  
Maria K. Peltola ◽  
Joel S. Lehikoinen ◽  
Lauri T. Sippola ◽  
Kauko Saarilahti ◽  
Antti A. Mäkitie
Keyword(s):  
Quality Of Life ◽  
Pilot Study ◽  
Side Effects ◽  
Head And Neck ◽  
Cancer Patients ◽  
Early Stage ◽  
Patient Reported Outcome ◽  
Patient Reported

Introduction The patient's role in toxicity reporting is increasingly acknowledged. There is also a need for developing modern communication methods between the patient and the medical personnel. Furthermore, the increasing number of head and neck cancer (HNC) patients is reflected in the volume of treatment follow-up visits, which remains a challenge for the health care. Electronic patient-reported outcome (ePRO) measures may provide a cost-efficient way to organize follow-up for cancer patients. Materials and Methods We tested a novel ePRO application called Kaiku®, which enables real-time, online collection of patient-reported outcomes, such as side effects caused by treatment and quality of life. We conducted a pilot study to assess the suitability of Kaiku® for HNC patients at the Department of Oncology, Helsinki University Hospital, Helsinki, Finland. Patients used Kaiku® during and one month after radiotherapy to report treatment-related side effects and quality of life. Two physicians and a nurse performed the practical electronic communication part of the study. Results Five of the nine patients agreed to participate in the study: three of them had local early-stage larynx cancer (T2N0, T1aN0, and T2N0) and the remaining two patients had early-stage base of tongue cancer (T2N0 and T1N2b). The degree of side effects reported by the patients via Kaiku® ranged from mild to life threatening. The number of outcome data points on patients' progress was significantly increased, which resulted in a better follow-up and improved communication between the patient and the care team. Conclusions Kaiku® seems to be a suitable tool to monitor side effects and quality of life during and after radiotherapy among HNC patients. Kaiku® and similar tools could be useful in organizing a cost-effective follow-up process for HNC patients. We recommend conducting a larger study to further assess the impact of an ePRO solution in routine clinical practice. • ePRO solutions may aid in the follow-up for cancer patients. • They seem suitable to monitor, for example, side effects and quality of life. • These systems ensure fast patient-driven reporting.

Patients' preferences concerning follow‐up after curative head and neck cancer treatment: A cross‐sectional pilot study

Head & Neck ◽  
2019 ◽  
Vol 41 (7) ◽  
pp. 2174-2181 ◽  
Author(s):  
Simon Andreas Mueller ◽  
Julia Riggauer ◽  
Olgun Elicin ◽  
Daniela Blaser ◽  
Sven Trelle ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Pilot Study ◽  
Cancer Treatment ◽  
Head And Neck ◽  
Neck Cancer ◽  
Cross Sectional

scholarly journals PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study

F1000Research ◽  
2021 ◽  
Vol 9 ◽  
pp. 1350
Author(s):  
Julian Rogasch ◽  
Marcus Beck ◽  
Carmen Stromberger ◽  
Frank Hofheinz ◽  
Pirus Ghadjar ◽  
...  
Keyword(s):  
Pilot Study ◽  
Head And Neck ◽  
Contrast Enhancement ◽  
Squamous Cell ◽  
Fdg Pet ◽  
Squamous Cell Carcinomas ◽  
Prospective Pilot Study ◽  
Contrast Enhanced ◽  
Pet Ct ◽  
Adc Values

Background: Tumor hypoxia measured by dedicated tracers like [18F]fluoromisonidazole (FMISO) is a well-established prognostic factor in head and neck squamous cell carcinomas (HNSCC) treated with definitive chemoradiation (CRT). However, prevalence and characteristics of positron emission tomography (PET) measured hypoxia in patients with relapse after previous irradiation is missing. Here we report imaging findings of a prospective pilot study in HNSCC patients treated with re-irradiation. Methods: In 8 patients with recurrent HNSCC, diagnosed at a median of 18 months after initial radiotherapy/CRT, [18F]fluorodeoxyglucose (FDG)-PET/CT (n=8) and FMISO-PET/MRI (n=7) or FMISO-PET/CT (n=1) were performed. Static FMISO-PET was performed after 180 min. MRI sequences in PET/MRI included diffusion-weighted imaging with apparent diffusion coefficient (ADC) values and contrast enhanced T1w imaging (StarVIBE). Lesions (primary tumor recurrence, 4; cervical lymph node, 1; both, 3) were delineated on FDG-PET and FMISO-PET data using a background-adapted threshold-based method. SUVmax and SUVmean in FDG- and FMISO-PET were derived, as well as maximum tumor-to-muscle ratio (TMRmax) and hypoxic volume with 1.6-fold muscle SUVmean (HV1.6) in FMISO-PET. Intensity of lesional contrast enhancement was rated relative to contralateral normal tissue. Average ADC values were derived from a 2D region of interest in the tumor. Results: In FMISO-PET, median TMRmax was 1.7 (range: 1.1-1.8). Median HV1.6 was 0.05 ml (range: 0-7.3 ml). Only in 2/8 patients, HV1.6 was ≥1.0 ml. In FDG-PET, median SUVmax was 9.3 (range: 5.0-20.1). On contrast enhanced imaging four lesions showed decreased and four lesions increased contrast enhancement compared to non-pathologic reference tissue. Median average ADC was 1,060 ×106 mm2/s (range: 840-1,400 ×106 mm2/s). Conclusions: This pilot study implies that hypoxia detectable by FMISO-PET may not be as prevalent as expected among loco-regional recurrent, HPV negative HNSCC. ADC values were only mildly reduced, and contrast enhancement was variable. The results require confirmation in larger sample sizes.

Sign in / Sign up

Export Citation Format

Share Document